Herbalife Q2 net sales $1.3B near guidance mid; adjusted EBITDA $173.6M beats; raises 2025 outlook

HERBALIFE LTD.

2025-Q2 EPS reported $0.97 revenue$2,480,800,000

Net sales of $1.3B down 1.7% YoY (flat constant currency); net income $49.3M, diluted EPS $0.48.
Adjusted EBITDA $173.6M exceeded guidance; Credit Agreement EBITDA $192.4M; leverage ratio 3.0x.
Adjusted net income $60.5M; adjusted diluted EPS $0.59.
Raised full-year net sales and adjusted EBITDA guidance; launched MultiBurn supplement in July.
Unveiled beta version of Pro2col digital platform and healthy lifespan supplement at July event.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-072568
form_type: 8-K
ticker: HLF
cik: 0001180262
company_name: HERBALIFE LTD.
filed_at: 2025-08-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.502981+00:00
generated_at: 2026-05-17T18:55:53.568196+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-072568
json_url: https://secwatch.observer/filing/0001213900-25-072568.json
markdown_url: https://secwatch.observer/filing/0001213900-25-072568.md
text_url: https://secwatch.observer/filing/0001213900-25-072568.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1180262/000121390025072568/0001213900-25-072568-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1180262/000121390025072568/ea0251917-8k_herbalife.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-25-072568

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.